Florastor products to be sold at CVS/pharmacy
SAN BRUNO, Calif. As part of its continued expansion throughout the U.S. retail market, Biocodex, the U.S. distributor of Florastor and Florastor Kids, has secured distribution through CVS/pharmacy beginning this month, the company announced. Florastor will be placed on-shelf in the stomach/digestives aisle, while Florastor Kids will be available upon request behind the counter.
According to Dan Harper, director of sales for Biocodex, the stomach/digestives aisle is the most appropriate spot for this product – in the company of popular anti-diarrheal remedies.
“While Florastor is technically a dietary supplement, it is used successfully by many to manage digestive ailments and diarrhea, so it makes sense for it to be available in the section where the consumer will be looking for those types of items,” Harper said.
“When Florastor was first introduced to Americans, the idea of probiotics was not well understood by mainstream consumers or even traditional medical practitioners,” stated Marc Rohman, U.S. VP and GM of Biocodex. “However, as Americans are becoming increasingly aware of the benefits of probiotics, particularly yeast-based probiotics such as Florastor, expanding distribution into the chain stores was the next logical step to meet the demand we’re seeing.”
According to Rohman, sales of Florastor have grown annually, even without widespread on-shelf availability, as a result of increased pharmacist and consumer awareness of the probiotic category, word-of-mouth and physician recommendations.
The latest chain shelf space acquisitions are the result of Biocodex’s work with Morgan & Sampson USA, with which Biocodex teamed to help manage its growth and distribution within the U.S. retail trade.
Ulcerative colitis treatment reduces need for surgery by almost half, study suggests
NEW YORK A new study led by Mayo Clinic researchers found that ulcerative colitis patients had a 41% reduction in colectomy when treated with infliximab for one year, according to a study published in the October 2009 issue of Gastroenterology.
Ulcerative colitis, an inflammatory bowel disease that causes chronic inflammation of the colon, is characterized by abdominal pain and diarrhea. Like Crohn’s disease, another common IBD, ulcerative colitis can be debilitating and often lead to colectomy, or surgical removal of the colon.
In the study, 728 patients received placebo or infliximab (5 or 10 mg/kg) for 46 weeks and were monitored for hospitalization or surgical outcomes. Eighty-seven percent had complete follow-up for the endpoint of whether or not they had colectomy, while the remaining 13% of patients had follow-up for less then a year, with a median follow-up of 6.2 months in these patients. The research showed that treatment with infliximab at zero, two, six and then every 8 weeks, reduced the incidence of colectomy through 54 weeks by 41% in outpatients with moderately-to-severe active ulcerative colitis.
Infliximab is an artificial antibody that works by blocking tumor necrosis factor alpha, a chemical messenger and a key part of the immune reaction. Infliximab blocks the action of TNF alpha by preventing it from binding to its receptor in the cell.
“Our purpose in this study was to see if the use of infliximab for ulcerative colitis would reduce the need for surgery,” said William Sandborn, M.D., a Mayo Clinic gastroenterologist and lead author of the study. “We found that treatment with infliximab reduced the need for colectomy by 41% compared to patients treated with placebo.”
Previous research has shown that infliximab therapy induced clinical remission and bowel healing for colitis patients. This new research provides more information and options for patients struggling with this difficult disease, explained Sandborn.
New report projects 12.6% increase of probiotics market
WILMINGTON, Del. The food and beverage practice at MarketsandMarkets projected the global probiotics market to be worth $32.6 billion by 2014, growing at a compound annual growth rate of 12.6% from 2009 to 2014 during its “Analyst Briefing Presentation on the Global Probiotic Market” held Tuesday.
Europe and Asia are expected to account for nearly 42% and 30% of the total revenues, respectively, in 2014. The U.S. market has opened up to these products in the recent past and is expected to grow at a CAGR of 17% from 2009 to 2014, the biggest contributor being probiotic cultured drinks followed by probiotic yogurts. Though the market base of probiotic products is comparatively lesser in the United States, the market is expected to grow at a rate of almost 14% in the same period driven by the large-scale acceptance of probiotic yogurts, probiotic cultured drinks and probiotic dietary supplements.
“The early movers in the industry will benefit in terms of market share but it is important that they focus on innovating probiotic strains that are more efficient in terms of survivability in harsh conditions and stability and are supported by competitively-priced production technologies,” the company stated. “In addition, garnering faith of the consumers by making substantiated and legitimate assertions in terms of health benefits will profit the market in future.”